The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Pacific Biosciences of California Inc’s current trading price is -61.41% away from its 52-week high, while its distance from the 52-week low is 23.32%. The stock’s price range for this period has been between $0.85 and $2.72 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 2.07 million for the day, a number notably lower than the average daily volume of 8.85 million over the last three months.
Pacific Biosciences of California Inc saw a rather unpredictable run in, in terms of market performance.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Pacific Biosciences of California Inc (PACB) has experienced a quarterly decline of -22.25% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 314.97M and boasts a workforce of 575 employees.
Analyzing Trading Volume and Moving Average Trends
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 7.63. Similarly, the long-term debt-to-equity ratio is also 7.60.
PACB Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The index has shown a price loss of -42.64% this year. Over the last six months, there has been a stronger performance of -40.36%. The price of PACB leaped by -7.12% during the last 30 days period. For the last 5-days stocks have improved 15.32%.
